Sana biotechnology congratulates senior vice president and head of t cell therapeutics, terry fry, m.d., on additional role at the university of colorado's gates institute

Seattle, may 12, 2022 (globe newswire) -- sana biotechnology, inc. (nasdaq: sana), a company focused on creating and delivering engineered cells as medicines, today announced that its senior vice president and head of t cell therapeutics, terry fry, m.d. will become an executive director at the prestigious university of colorado gates institute. dr. fry, a world-renowned expert in chimeric antigen receptor t cell (car t) therapies, has devoted part of his time to the university of colorado as a clinical professor of pediatric oncology since joining sana. he continues to work in his current sana role without change while serving as the institute's executive director.
SANA Ratings Summary
SANA Quant Ranking